These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 9007086)

  • 1. Apolipoprotein E and inclusion body myositis.
    Garlepp MJ; Mastaglia FL
    Ann Neurol; 1996 Dec; 40(6):826-8. PubMed ID: 9007086
    [No Abstract]   [Full Text] [Related]  

  • 2. Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies.
    Mirabella M; Alvarez RB; Engel WK; Weisgraber KH; Askanas V
    Ann Neurol; 1996 Dec; 40(6):864-72. PubMed ID: 9007091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular pathology and pathogenesis of inclusion-body myositis.
    Askanas V; Engel WK
    Microsc Res Tech; 2005 Jul; 67(3-4):114-20. PubMed ID: 16104000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy.
    Askanas V; Engel WK; Mirabella M; Weisgraber KH; Saunders AM; Roses AD; McFerrin J
    Ann Neurol; 1996 Aug; 40(2):264-5. PubMed ID: 8773613
    [No Abstract]   [Full Text] [Related]  

  • 5. Upregulation of Fas/Fas ligand in inclusion body myositis.
    Fyhr IM; Oldfors A
    Ann Neurol; 1998 Jan; 43(1):127-30. PubMed ID: 9450780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model.
    Wojcik S; Nogalska A; McFerrin J; Engel WK; Oledzka G; Askanas V
    Neuropathol Appl Neurobiol; 2007 Apr; 33(2):238-42. PubMed ID: 17359364
    [No Abstract]   [Full Text] [Related]  

  • 7. New developments in the myositis syndromes.
    Kagen LJ
    Bull Rheum Dis; 1996 Oct; 45(6):1-4. PubMed ID: 8885477
    [No Abstract]   [Full Text] [Related]  

  • 8. Creutzfeldt-Jakob disease and inclusion body myositis: abundant disease-associated prion protein in muscle.
    Kovacs GG; Lindeck-Pozza E; Chimelli L; Araújo AQ; Gabbai AA; Ströbel T; Glatzel M; Aguzzi A; Budka H
    Ann Neurol; 2004 Jan; 55(1):121-5. PubMed ID: 14705121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers.
    Wójcik S; Engel WK; McFerrin J; Askanas V
    Acta Neuropathol; 2005 Aug; 110(2):173-7. PubMed ID: 15983828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear membrane proteins are present within rimmed vacuoles in inclusion-body myositis.
    Greenberg SA; Pinkus JL; Amato AA
    Muscle Nerve; 2006 Oct; 34(4):406-16. PubMed ID: 16823856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion-body myositis and Alzheimer disease: two sides of the same coin, or different currencies altogether?
    Murphy MP; Golde TE
    Neurology; 2006 Jan; 66(2 Suppl 1):S65-8. PubMed ID: 16432148
    [No Abstract]   [Full Text] [Related]  

  • 12. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis.
    Askanas V; Engel WK
    Curr Opin Rheumatol; 2007 Nov; 19(6):550-9. PubMed ID: 17917534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of in vitro muscle fiber function in dermatomyositis and inclusion body myositis: a single fiber study.
    Krivickas LS; Amato AA; Krishnan G; Murray AV; Frontera WR
    Neuromuscul Disord; 2005 May; 15(5):349-54. PubMed ID: 15833427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Messenger RNA degradation may be inhibited in sporadic inclusion body myositis.
    Nakano S; Shinde A; Ito H; Ito H; Kusaka H
    Neurology; 2005 Aug; 65(3):420-5. PubMed ID: 16087907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.
    Askanas V; Engel WK
    Neurology; 2006 Jan; 66(2 Suppl 1):S39-48. PubMed ID: 16432144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease.
    Kleopa KA; Kyriacou K; Zamba-Papanicolaou E; Kyriakides T
    Muscle Nerve; 2005 Feb; 31(2):260-5. PubMed ID: 15389648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nature of "Tau" immunoreactivity in normal myonuclei and inclusion body myositis.
    Salajegheh M; Pinkus JL; Nazareno R; Amato AA; Parker KC; Greenberg SA
    Muscle Nerve; 2009 Oct; 40(4):520-8. PubMed ID: 19626672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inclusion body myositis. Report of 4 cases].
    Basquiera AL; Caeiro F; Palacio S; Theaux R; Casale A; Lucero C; Alvarellos A
    Medicina (B Aires); 2002; 62(1):37-40. PubMed ID: 11965848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normal sialylation of serum N-linked and O-GalNAc-linked glycans in hereditary inclusion-body myopathy.
    Savelkoul PJ; Manoli I; Sparks SE; Ciccone C; Gahl WA; Krasnewich DM; Huizing M
    Mol Genet Metab; 2006 Aug; 88(4):389-90. PubMed ID: 16762577
    [No Abstract]   [Full Text] [Related]  

  • 20. Congenital myopathy with abundant ring fibres, rimmed vacuoles and inclusion body myositis-type inclusions.
    Fidziańska A; Kamińska A
    Neuropediatrics; 2003 Feb; 34(1):40-4. PubMed ID: 12690567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.